NCT04511988Active, not recruiting
Using Liquid Biopsy in Newly Diagnosed Patients With High Grade Adenocarcinoma of Ovarian Origin, Fallopian Tubes or Primary Peritoneal
Evaluation of Clonal Heterogeneity and Tumor Evolution Using Liquid Biopsy in Newly Diagnosed Patients With High Grade Adenocarcinoma of Ovarian Origin, Fallopian Tubes or Primary Peritoneal
Source: ClinicalTrials.gov · Last updated 16 Sept 2025
Brief summary (registry, in English)
BOVARY-CE is a monocentric, pilot, longitudinal, real-life study with a total duration of 36 months. The purpose of this study is to assess the feasibility of using liquid biopsy as a substitute for tissue multisampling, in order to describe clonal heterogeneity and tumor evolution in patients with ovarian cancer. The method involves the inclusion of 20 patients with high-grade ovarian adenocarcinoma, fallopian tubes or primary peritoneal origin, not pretreated, newly diagnosed, and eligible for treatment who will participate in the research. These patients will have several samples throughout their treatment for a period of 2 years: blood samples which will be taken at each therapeutic moment of interest. Tissue samples which will be taken at the time of the diagnostic laparoscopy and at the time of surgery. The concentration of cfDNA and tumor heterogeneity will be used to predict disease-related events defined as relapse, progression or death.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 11 Aug 2020
- Start date
- 17 Jul 2021
- Primary completion date
- 31 Jul 2026
- Lead sponsor
- Institut de Cancérologie de Lorraine
- Diseases
- Ovarian cancer
- NCT number
- NCT04511988
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 17 Jul 2021 to the primary completion date, 31 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study
Other illness
- Ongoing treatment for the newly diagnosed cancer or the recurrence
- Other cancers treated within the last 5 years
Age
- Age \< 18 years
Other
- Contraindication to blood samples of 20 mL
- Pregnant or breast-feeding women
- Patient under guardianship or curatorship or deprived of liberty
Who the study is looking for
- Age ≥ 18 years
- Patient with non-treated high grade serous and endometrioid carcinoma of ovarian, fallopian tube, or primary peritoneal origin proven cytologically or histologically at inclusion and eligible for treatment
- Patient eligible for an upfront surgery or pretherapeutic coelioscopy
- Adequate haemoglobin rate ≥ 9 g/dL
- Patient affiliated to a social security scheme
- Ability to provide written informed consent
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut de Cancérologie de Lorraine Coordinator of this site? Confirm its status | Vandœuvre-lès-Nancy | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.